# Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old

> **NCT03199053** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 256 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Saxagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03199053
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-11
- **Primary completion:** 2023-02-01
- **Final completion:** 2024-01-03
- **Target enrollment:** 256 (ACTUAL)
- **Last updated:** 2024-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03199053

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03199053, "Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03199053. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*